Immunotherapy News and Research

Latest Immunotherapy News and Research

Cancer immunotherapies promise to be a new tool in fight against cancer

Drugs that direct a cancer patient's immune system to eradicate her or his disease, known as cancer immunotherapies, promise to be a new tool in the fight against cancer. Since the Koch Institute's inception, exploring the close relationship between the immune system and cancer has been one of the Institute's priority research areas.

9 Jul 2013

Probiodrug to present studies on PQ912 for treatment of Alzheimer's disease at AAIC meeting

Probiodrug AG (Probiodrug) announced that it will be making two poster and two oral presentations at the upcoming Alzheimer's Association International Conference in Boston, MA July 13 - 18, 2013.

8 Jul 2013

MGN1703 drug provides a new treatment approach to colorectal cancer

New data on an emerging treatment that aims to fight colorectal cancer by stimulating the immune system have been presented at the ESMO 15th World Congress on Gastrointestinal Cancer.

4 Jul 2013

GAPVAC aims to develop personalized therapeutic vaccines for cancer

A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.

4 Jul 2013

Assay identifies T cells as most capable of fighting infections and cancers

The idea of fighting infections and even cancers by inducing protective immune responses may now be a step closer to clinical practice. Researchers have removed a major obstacle to widespread use of so-called adoptive transfer therapy, in which a patient receives "killer" immune cells targeting a disease agent. Existing technologies can easily provide T cells that will recognize a specific antigen, but it has been challenging to identify individual cells most likely to succeed in fighting the disease - until now.

4 Jul 2013

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.

30 Jun 2013

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.

25 Jun 2013

Penn researchers find ALS disease progresses in a stepwise, sequential pattern

The motor neuron disease Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, progresses in a stepwise, sequential pattern which can be classified into four distinct stages, report pathologists with the Perelman School of Medicine at the University of Pennsylvania in the Annals of Neurology.

20 Jun 2013

OncoSec Medical completes enrollment in ImmunoPulse trial for metastatic melanoma patients

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the completion of patient enrollment in a Phase II clinical trial of ImmunoPulse for metastatic melanoma patients.

18 Jun 2013

RetroNectin reagent now available for gene therapy clinical research

In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin reagent for direct supply to biomedical researchers.

17 Jun 2013

New collaboration to advance cancer immunotherapy research

The Cancer Research Institute, the Ludwig Institute for Cancer Research and Immune Design, a biotech company focused on immune-based therapies for cancer and other human diseases, today announced that they have signed a collaboration agreement to advance cancer immunotherapy research.

13 Jun 2013

Clinical trial underway for potential new treatment for type 1 diabetes

A clinical trial is underway for a potential new treatment for type 1 diabetes that could eventually mean patients are able to reduce insulin treatment from several times a day to only once or twice a week. The new treatment is a direct result of research to understand the genetics of the disease.

11 Jun 2013

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, signed a Sponsored Research Agreement with Old Dominion University and the Frank Reidy Research Center for Bioelectrics.

11 Jun 2013

Allergic rhinitis treatments: an interview with Dr Dermot Ryan, GP and allergy expert

Allergic rhinitis is most commonly recognized as hay fever in the United Kingdom and it is due to the impact of an allergen, in the case of hay fever a pollen, setting off an inflammatory response in the lungs, causing typical symptoms...

5 Jun 2013

Smoke exposure puts infants with respiratory infections at risk for longer hospital stays

More evidence has surfaced that supports the war on smoking, especially if smokers have an infant in their household. A study published today in the June issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), found that infants with a family history of allergic disease with lower respiratory tract infections, who are exposed to secondhand smoke are at risk for longer hospital stays.

5 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Precision Biologics, in collaboration with investigators from Duke University, has been selected to present an abstract of findings from its Phase 2 clinical trial at the Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2013

BACH2 gene may play a central role in the development of allergic and autoimmune diseases

Scientists at the National Institutes of Health, and their colleagues, have discovered that a gene called BACH2 may play a central role in the development of diverse allergic and autoimmune diseases, such as multiple sclerosis, asthma, Crohn's disease, celiac disease, and type-1 diabetes.

4 Jun 2013

NewLink Genetics announces results from two clinical studies with indoximod

NewLink Genetics Corporation, an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway.

3 Jun 2013

Immunotherapy News and Research

Latest Immunotherapy News and Research

Cancer immunotherapies promise to be a new tool in fight against cancer

Probiodrug to present studies on PQ912 for treatment of Alzheimer's disease at AAIC meeting

MGN1703 drug provides a new treatment approach to colorectal cancer

GAPVAC aims to develop personalized therapeutic vaccines for cancer

Assay identifies T cells as most capable of fighting infections and cancers

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Penn researchers find ALS disease progresses in a stepwise, sequential pattern

OncoSec Medical completes enrollment in ImmunoPulse trial for metastatic melanoma patients

RetroNectin reagent now available for gene therapy clinical research

New collaboration to advance cancer immunotherapy research

Clinical trial underway for potential new treatment for type 1 diabetes

OncoSec Medical signs Sponsored Research Agreement with ODU for melanoma study

Allergic rhinitis treatments: an interview with Dr Dermot Ryan, GP and allergy expert

Smoke exposure puts infants with respiratory infections at risk for longer hospital stays

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

BACH2 gene may play a central role in the development of allergic and autoimmune diseases

NewLink Genetics announces results from two clinical studies with indoximod

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in